US WorldMeds is Now Distributing XADAGO® (Safinamide) in the U.S. for PD Patients

(July 11, 2017) - Alliance partners Newron Pharmaceuticals S.p.A. and Zambon S.p.A. based in Milan, and Louisville-based US WorldMeds announced today that XADAGO (safinamide) is now available as an add-on therapy for U.S. patients with Parkinson’s disease (PD) currently taking levodopa/carbidopa and experiencing “off” episodes. XADAGO, a once-daily tablet, is the first New Chemical Entity approved in the U.S. for PD-related motor fluctuations in more than a decade for the estimated 1 million patients currently affected by PD. Read more